MoonLake Immunotherapeutics (MLTX) Retained Earnings (2020 - 2026)

MoonLake Immunotherapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at $786.3 million for Q1 2026.

• On a quarterly basis, Retained Earnings rose 32841.47% year-over-year to $786.3 million in Q1 2026; TTM through Mar 2026 was $786.3 million, a 32841.47% increase from a year earlier, with the FY2025 full-year figure at -$462.9 million, down 9363.78% from the prior year.
• Retained Earnings rose to $786.3 million in Q1 2026 per MLTX's latest filing, from -$462.9 million in the prior quarter.
• Across five years, Retained Earnings topped out at $786.3 million in Q1 2026 and bottomed at -$462.9 million in Q4 2025.
• The 5-year median for Retained Earnings is $3.3 million (2024), against an average of $173.5 million.
• Across the five-year window, Retained Earnings sank 33340.86% in 2023 and surged 32841.47% in 2026, its largest moves.
• Year by year, Retained Earnings stood at $350946.0 in 2022, then sank by 33340.86% to -$116.7 million in 2023, then jumped by 104.28% to $5.0 million in 2024, then slumped by 9363.78% to -$462.9 million in 2025, then soared by 269.86% to $786.3 million in 2026.
• Per Business Quant, the three latest MLTX Retained Earnings figures stand at $786.3 million (Q1 2026), -$462.9 million (Q4 2025), and $689.1 million (Q3 2025).